Can ctDNA Guide Radiation Use in Oligometastatic NSCLC? Detectable circulating tumor DNA before radiotherapy linked with worse survival Oct 05, 2023
Drugmaker Plans to Pull Lung Cancer Therapy From the Market Randomized trial of mobocertinib (Exkivity) failed to confirm benefit in rare tumor type Oct 04, 2023
FDA Staff Highly Skeptical of Confirmatory Data on KRAS Inhibitor in NSCLC Reviewers see potentially tiny PFS benefit with sotorasib, raise concerns over "systemic bias" Oct 04, 2023
Anti-TIGIT Plus Immunotherapy 'Promising' in NSCLC, Esophageal Cancer Combination may "provide meaningful antitumor activity," researchers say Sep 28, 2023
Cancer Drug Shortages for Kids; Pharma Agrees to Price Talks; Catch-Up on Screening News, features, and commentary about cancer-related issues Sep 28, 2023
The White House Cancer Moonshot Is a Dud We're failing to take simple steps to reduce one of the biggest causes of cancer Sep 22, 2023
TikTok Dinged for Misinformation; BRCA Risk Overestimated; Cheers for Oncology News, features, and commentary about cancer-related issues Sep 21, 2023
Another Win for Biomarker-Driven Thromboprophylaxis for Patients With Cancer Threefold risk reduction with enoxaparin in high-risk gastrointestinal, lung cancers Sep 21, 2023
Cisplatin Shortage Eases; Air Pollution Linked to Breast Cancer; Pap Test Confusion News, features, and commentary about cancer-related issues Sep 15, 2023
Individualized SABR for Lung Tumors Yields Low Recurrence Rates Strategy also results in low rates of severe toxic effects Sep 14, 2023
IMRT Best for Locally Advanced NSCLC, Study Suggests Technique reduces risk of severe lung toxicity and radiation to the heart compared with 3D-CRT Sep 13, 2023
Novel Antibody-Drug Conjugate Shows Efficacy in Advanced EGFR-Mutated NSCLC Confirmed responses reached 29.8% in heavily pretreated patients Sep 13, 2023
Study Questions Use of Aggressive Surgery in Early Mesothelioma Randomized data suggest surgery increases risk of death by 28% over first 42 months Sep 12, 2023
Adding First-Line Chemo Boosts PFS in EGFR-Mutant Lung Cancer Osimertinib plus chemotherapy improved PFS by nearly 9 months versus targeted agent alone Sep 12, 2023
First-Line Triplet Yields 'Striking' OS Result in Extensive-Stage SCLC Median overall survival reached 19.3 months in Chinese trial Sep 11, 2023
How the Chemotherapy Shortage Is Affecting Frontline Clinicians "How are we here in 2023 having some of these discussions?" bemoans gynecologic cancer expert Sep 08, 2023 video
Microdevices for Glioma; Cervical Adenocarcinoma Test; Language Gaps and Cancer Care News, features, and commentary about cancer-related issues Sep 07, 2023
Prayer to Cure Cancer; Exercise for Sexual Dysfunction; Carb Intake and Cancer News, features, and commentary about cancer-related issues Sep 01, 2023
Novel KRAS Inhibitor Leads to Durable Responses in Multiple Tumor Types More than half of patients with NSCLC, more than a third of those with CRC responded to divarasib Aug 23, 2023
Removing Race-Corrected Pulmonary Function Tests May Alter Lung Cancer Care Path to eliminating these tests, while crucial, will be challenging, researchers say Aug 16, 2023
Multi-Cancer Early Detection: 20th-Century Fiction Becomes Reality These tests could soon become a valuable addition to current cancer screening tools Aug 01, 2023
Immunotherapy Added to SABR Improves Event-Free Survival in Early NSCLC Approach is "potentially practice-changing," editorialist says Jul 20, 2023
Some NSCLC Patients on ICI Therapy Fare Worse With Proton Pump Inhibitor Use But PFS, OS longer with ICIs plus chemotherapy among patients treated with PPIs Jul 11, 2023
Pushback on Price Negotiation; Genetic Testing Lags; More Foreign Help for Shortages News, features, and commentary about cancer-related issues Jun 15, 2023
Hooray! A Clearer Estimate of Your Risk for Death Is Here Researchers do the legwork to incorporate smoking status into NCI's "Know Your Chances" website Jun 09, 2023
TTFields Therapy Yields OS Improvement in Second-Line NSCLC However, device was not tested alongside current standard of care, expert points out Jun 08, 2023
Checkpoint Blockade Stumbles in Advanced EGFR-Mutant NSCLC "Immediate changes" needed to patient care to avoid unnecessary toxicity, says ASCO expert Jun 07, 2023
Certain NSCLC Patients May Be Able to Stop Immunotherapy at 2 Years Retrospective study finds no difference in OS between patients who stop and those who continue Jun 06, 2023
New Data in NSCLC Bolster Support for Perioperative Immunotherapy EFS benefit with pembrolizumab in KEYNOTE-671, but no OS benefit "yet," says investigator Jun 05, 2023
New Standard in Operable EGFR-Positive Lung Cancer "We should firmly close the door on one-size-fits-all treatment," says ASCO expert Jun 04, 2023
Lung Cancer Screening Results Influence Follow-Up Adherence Study suggests groups to target for enhanced outreach to encourage regular screening May 25, 2023
Drug Shortages Hit Oncology; Telemedicine Tops In-Person; Sniffing Out Lung Cancer News, features, and commentary about cancer-related issues May 12, 2023
'Potential' New Option for Operable NSCLC Adding perioperative durvalumab to neoadjuvant chemo improved pCR rates, event-free survival Apr 17, 2023
FDA Allows Lower Risk Designation for Snuff Product The brand joins a limited few granted modified risk tobacco claims Mar 16, 2023
'Winners' and 'Losers'; Mandated Sick Leave and Cancer Screening; More AI Advances News, features, and commentary about cancer-related issues Mar 03, 2023
Cancer Drugs That Didn't Work; Another HIV Cure; Kiss of Success With Mistletoe News, features, and commentary about cancer-related issues Feb 24, 2023
AI Tool Forecasts Lung Cancer Risk From a Single CT Scan Experts give high marks to performance of "Sybil" in predicting disease over 6 years Feb 07, 2023
Risk Model-Based Lung Cancer Screening More Cost-Effective Than USPSTF Recs Risk prediction models more sensitive than age-, smoking history-based methods Feb 07, 2023
Bispecific Antibody Active in Relapsed/Refractory Small Cell Lung Cancer A majority of patients obtained disease control with tarlatamab; responses proved durable Feb 01, 2023
Immunotherapy Survival Gains 'Less Impressive' in Older Lung Cancer Patients Study finds median OS improvement of just 1 month for patients 75 and older Jan 26, 2023
